Jasper Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Velan Capital Investment Management LP and affiliated entities have increased their beneficial ownership in Jasper Therapeutics, Inc. to 9.88% following the company's acquisition of Kira Pharmaceuticals.
NASDAQ
Velan Capital and affiliated entities increased their beneficial ownership in Jasper Therapeutics, Inc. to 9.6% through a recent public offering, acquiring additional shares and warrants.